CX3CL1 and Alzheimer disease: Among all selected potential biomarkers, only chemokines CX3CL1 and CXCL12 revealed clinical accuracy in discriminating MCI and AD (AUC = 0.788, 95% Cl 0.669–0.907, p < 0.001, and AUC = 0.766, 95% Cl 0.637–0.895, p < 0.001, respectively).